Aurobindo Pharma Eyes Break-Even in China by Q3 2026
Aurobindo Pharma anticipates its China facility to reach break-even by the third quarter of the fiscal year 2026. Despite a recent 10% drop in profits, investments in new facilities and product launches in the US and Europe are set to bolster growth and improve margins.
- Country:
- India
Aurobindo Pharma is poised to see its China facility achieve break-even status by the third quarter of fiscal year 2026, according to CFO Santhanam Subramanian. This development is expected as the company ramps up operations, following the commencement of production last November.
Significant investments are fueling these efforts, including around USD 145 million in the Chinese plant and USD 70 million across two US facilities, further expanding Aurobindo's manufacturing capacities. The firm's strategy also includes filing for over 20 new product approvals in the US and Europe, boosting revenue potential.
Despite a 10% decline in net profit due to weaker US and API business sales, Aurobindo remains optimistic about future growth. Subramanian expressed confidence in achieving a 20-21% margin by FY26, driven by new commercial operations and continued launch activities in critical markets.
(With inputs from agencies.)
Google News